Real-world effectiveness and drug retention rate of risankizumab in patients with psoriatic arthritis: data from the multicentre GIRRCS cohort
ABSTRACT Introduction Risankizumab, a selective inhibitor of the IL-23 p19 subunit, has shown efficacy in randomized trials in psoriatic arthritis (PsA); however, real-world data remain limited. We evaluated the effectiveness and treatment persistence of risankizumab in the GIRRCS cohort. Methods This observational stu...